Lilly's brenipatide shows 9 to 12.5 day half-life in Phase I
The GIP/GLP-1 dual agonist is being taken into Phase III trials in major depressive disorder and alcohol use disorder on a weekly maintenance schedule.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 19 13:31 ETSource: Genetic Engineering and Biotechnology News
The wire
- 01At Psych Congress 2026, Lilly presented Phase I data (NCT06606106) showing brenipatide mean half-life of 9.08 to 12.5 days across doses of 0.3 mg to 4.5 mg in healthy, overweight and obese participants.
- 02The candidate targets GIP and GLP-1 receptors in central nervous system and inflammatory pathways, a different positioning from tirzepatide, which with Zepbound generated over $27.6 billion for Lilly in the first half of 2026.
- 03Data are from a company-sponsored dose-selection study in healthy and obese volunteers, not patients; efficacy in depression and alcohol use disorder remains untested in the Phase III program now running.
From the source
Read at genengnews.comLilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders
Eli Lilly presented early positive clinical data supporting once-weekly dosing for its GIP/GLP-1 receptor agonist candidate brenipatide in substance use, psychiatric, and immunologic disorders—and detailed the design of Phase III trials that will assess the drug in major depressive disorder (MDD) and alcohol use disorder (AUD).